成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

立即打開
Pharma and biotech: is there love?

Pharma and biotech: is there love?

David Ewing Duncan 2010年05月13日

????For at least a decade, anyone following the life sciences industry has noticed two naked truths.

????One is that the biggest pharmaceutical companies are struggling to replenish research development pipelines as their billion-dollar blockbuster drugs go off patent and in-house programs falter, all despite having spent billions on research and development.

????The other is that biotechnology companies often have the best ideas for new drugs but are constantly short of cash.

????This is hardly new. Since the 1980s, pharma and biotech have forged relationships, most of them driven by the expedience of pharma companies trying to fill in what they considered short-term gaps in their own internal R&D. Lately, though, the relationship is getting serious.

????The world's drug development pipeline is becoming a real couple. That key message emerged from the annual mega-meeting of the Biotechnology Industry Organization (BIO) last week in Chicago.

????"We're recognizing that we don't have the expertise to do everything," says Barry Gertz, senior vice president for global clinical development at Merck (MRK, Fortune 500), a company whose revenues dropped after withdrawing the painkiller Vioxx from the market in 2004. Like other companies, Merck also has had drugs either fail to pass muster during human testing or they have fallen off patent. "There is a lot of science going on outside of Merck," says Gertz. "We have more chances of success if we go external."

????"The vast majority of new ideas are going to come from outside of pharma," says Jay Siegel, chief biotechnology officer for Johnson & Johnson (JNJ, Fortune 500) -- a recently created position at the company.

????The biotech sector's knack at innovation seems to come from the small size of most its companies, which reduces bureaucracy and complications, and a chronic underfunding that drives companies to be more nimble and creative in the research and early development phases. At the other end of the pipeline -- late-stage human clinical trials and manufacturing, sales, and marketing -- Big Pharma tends to be more adept.

????That's the basis of the marriage, and of the redesign in the pipeline, that's been de facto for several years, but now is being more formally consummated.

????"If we're honest, we were driven to tactically look outside when we had some slips in our production line," says Shaun Grady, vice president for corporate development at AstraZeneca. "Now it's an acknowledged strategy by our board."

????Pharma showed its love at the BIO event by deploying small armies of business development people to hold thousands of speed-dating sessions with biotech hopefuls during the four-day meeting.

????For instance, GlaxoSmithKline (GSK) brought 35 people who held 300 meetings. "A few years ago, we were nowhere with biotech," says Adrian Rawcliffe, head of business development for GlaxoSmithKline. "Now we have 100 people doing deals worldwide." Merck says they brought 40 people who heard 400 pitches, and AstraZeneca (AZN) brought 30 people to hold hundreds of meetings.

????For many deals, the courtship began during meetings at the big biotech financial meeting held every January in San Francisco by JP Morgan (JPM, Fortune 500).

????Rawcliffe says that his company has been spending hundreds of millions of dollars a year on biotech partnerships and acquisitions -- 10 to 20 large deals, 15 to 20 milestone deals, and an average of one major acquisition per annum. "This is likely to stay about the same for the foreseeable future," he says.

????Pharma also has been making deep cuts in their R&D expenditures after a decade of steep increases. Pfizer (PFE, Fortune 500) has announced plans to eliminate thousands of jobs and slice their R&D budget by $2 billion to $3 billion by 2012. And AstraZeneca says it will cut back by $1 billion in the next four years. This comes as the cost of developing new pharmaceuticals for some of the largest companies is approaching $4 to 5 billion dollars per drug. (This number comes from dividing the number of successful drugs by the total R&D budget, including failures).

掃碼打開財富Plus App
国产成人啪精品视频免费网站| 美女视频黄频A免费高清不卡| 欧美片内射欧美美美妇| 国产3p露脸在线视频| 国产激情一区二区三区APP| 久久久久国色AV免费观看| AV无码免费一区二区三区| 国产亚洲欧洲997久久综合| 国产精品午夜剧场免费观看| 欧美国产中文在线字幕视频| 中文乱码人妻系列一区二区| 亚洲精品无码AV中文字幕| 亚洲欧美日韩在线观看二区| 国产AV无码专区亚洲AWWW| 日本韩国欧美一区| 成人免费AV一区二区三区| 人妻少妇精品无码专区二区a| 欧美一区二区视频高清专区| 精品无码成人久久久久久| 亚洲人成无码www久久久| 最近中文字幕MV高清在线视频| 牲欲强的70岁熟妇农村老妇女| 日本丰满妇人成熟免费中文字幕| 国产综合亚洲专区在线视频免费| 无码A级毛片免费视频下载| 国产极品美女高潮无套| 国产亚洲蜜臀AV在线播放| 久久伊人少妇熟女大香线蕉| 特级无码毛片免费视频尤物| 午夜精品无人区乱码1区2区| 精品午夜福利在线视在亚洲| 欧美亚洲综合另类精品国产色拍| 91精品人妻一区二区三区蜜桃| 国产女人的高潮国语对白入口| 精品国产乱码久久久久久郑州公司| 欧美日韩永久免费看看视频| 美女把尿口扒开让男人桶爽| 国产成人久久精品二区三区| 97超碰人人模人人爽人人爱| 欧美精品成人久久网站| 国产精品麻豆成人AV电影|